Finally, the answer to question 51 is clearly “no,” without posing the other questions. Hence, the treatment of asthma is directed not only at the eosinophilic bronchitic component but also at the physiologic abnormalities. In the real world, the patient with severe asthma may also have chronic airflow limitation, infective bronchitis, and other respiratory or nonrespiratory diseases. The more specific hypothetic questions that Dr Peters1 poses are difficult to understand. In the first place, if the patient with asthma has no symptoms, a normal FEV1, presumably airway hyperresponsiveness to demonstrate current asthma, and no exacerbations, why are eosinophils being measured? In the converse question, Dr Peters1 implies that patients without sputum eosinophilia can respond clinically to corticosteroids. They can respond less often if the sputum eosinophils are between 1% and 3% but are very unlikely to respond if they are zero or virtually zero or if there is another nonsteroid-responsive cause, such as a resolving viral infection.